Capital Allocation for Biotech Innovations

At our firm, we are prepared to allocate capital to promising biotech startups that are pioneering solutions to real-world health challenges. We are particularly interested in companies focused on drug development, diagnostics, and innovative medical technologies. Our investment can range from $250,000 to $5,000,000, aimed at helping businesses accelerate their research, expand their teams, and reach critical milestones. We seek to partner with dynamic founding teams who demonstrate a strong market understanding and have substantial traction in their respective fields.

Michael Harper, an independent investor with a track record of supporting early-stage biotech ventures. Known for a hands-on approach, we prioritize collaborations that foster innovation and development in healthcare.

Founders should have a robust business model, preferably existing proof of concept or product, and a clear strategy for market entry. Teams with scientific backgrounds or industry experience are particularly attractive.